Clinical Trials Tracker
Clinical Trials Tracker: Ketamine & Esketamine Studies
Registered studies are the earliest public signal of where ketamine research is heading. These listings come straight from the U.S. registry — Ketalux does not edit, rank, or summarize study results here.
Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: August 28, 2026Evidence: ClinicalTrials.gov registry data
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Quick answer
Does appearing in a clinical trial mean a treatment works?
No. Registration means a study has been planned and listed with a public registry. It says nothing about whether the intervention is safe or effective for the condition being studied — those conclusions require completed, peer-reviewed results.
Source and freshness
Listings are retrieved live from the ClinicalTrials.gov API each time you load this page. Always confirm eligibility, status, and contact details on the official study record before acting on anything here.
What these listings are — and are not
- A listing is a registration, not a result. It records that a study was planned and described publicly. Findings, if any, appear later in the registry's results section or in peer-reviewed publications.
- Recruitment status is not evidence. "Recruiting" means enrollment is open; it says nothing about safety, effectiveness or how the study will turn out.
- Ketalux does not endorse any trial, sponsor, investigator, site or provider shown here. Listings are reproduced as published by the registry, with no selection for or against any organization, and Ketalux has no financial or referral relationship with them.
- The data comes from ClinicalTrials.gov, the U.S. National Library of Medicine registry, through its public API. Ketalux does not edit, correct, estimate or add to the fields returned; blank fields are shown as "Not stated".
- "Data as of" is a retrieval timestamp, recording when this page last received data from the registry — not when a study changed and not when this page was edited.
- If the registry cannot be reached, the last successfully retrieved snapshot is shown unchanged, clearly labelled, with its own earlier retrieval time.
Data as of: — registry retrieval time. This is separate from the page's editorial last-updated date above.
- RECRUITINGPHASE2Updated 2026-10-09
Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department
- Conditions:
- Suicidal Ideation
- Interventions:
- Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning
- Sponsor:
- The University of Texas Health Science Center at San Antonio
- Enrollment:
- 200 participants
- Start:
- 2026-09-30
- Primary completion:
- 2028-09-30
- Locations:
- Fort Hood, Texas, United States · San Antonio, Texas, United States
- Identifier:
- NCT07868913
- RECRUITINGPHASE1Updated 2026-10-08
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Conditions:
- Healthy Volunteer, Major Depressive Disorder, Depression
- Interventions:
- Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 150 participants
- Start:
- 2017-05-25
- Primary completion:
- 2027-01-01
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT03065335
- RECRUITINGEARLY PHASE1Updated 2026-10-07
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
- Conditions:
- Major Depressive Disorder (MDD)
- Interventions:
- Ketamine only
- Sponsor:
- University of Pennsylvania
- Enrollment:
- 10 participants
- Start:
- 2026-04-01
- Primary completion:
- 2026-12-15
- Locations:
- Philadelphia, Pennsylvania, United States
- Identifier:
- NCT06788249
- RECRUITINGPHASE2Updated 2026-10-05
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Conditions:
- Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- Interventions:
- ACP-211, Placebo
- Sponsor:
- ACADIA Pharmaceuticals Inc.
- Enrollment:
- 153 participants
- Start:
- 2025-11-14
- Primary completion:
- 2027-08
- Locations:
- Birmingham, Alabama, United States · Chino, California, United States · Glendale, California, United States · La Jolla, California, United States
- Identifier:
- NCT07284667
- RECRUITINGPHASE2Updated 2026-10-05
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- Conditions:
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
- Interventions:
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 50 participants
- Start:
- 2024-11-06
- Primary completion:
- 2027-07-01
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT06511908
- RECRUITINGPHASE1Updated 2026-10-02
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
- Conditions:
- Pain, Postpartum Depression
- Interventions:
- Ketamine (Ketalar)
- Sponsor:
- University of Utah
- Enrollment:
- 50 participants
- Start:
- 2025-03-28
- Primary completion:
- 2027-12-07
- Locations:
- Pittsburgh, Pennsylvania, United States · Salt Lake City, Utah, United States
- Identifier:
- NCT06767566
- RECRUITINGUpdated 2026-10-01
Long-term Observation of Participants With Mood Disorders
- Conditions:
- Depression, Suicide Risk
- Interventions:
- Not stated
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 1000 participants
- Start:
- 2021-08-17
- Primary completion:
- 2028-10-01
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT04877977
- RECRUITINGPHASE2PHASE3Updated 2026-09-30
Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
- Conditions:
- Suicide
- Interventions:
- Ketamine Hydrochloride, Crisis Response Plan
- Sponsor:
- The University of Texas Health Science Center at San Antonio
- Enrollment:
- 24 participants
- Start:
- 2023-01-06
- Primary completion:
- 2026-12-31
- Locations:
- San Antonio, Texas, United States
- Identifier:
- NCT05696691
- RECRUITINGPHASE3Updated 2026-09-25
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Interventions:
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Sponsor:
- Janssen Research & Development, LLC
- Enrollment:
- 348 participants
- Start:
- 2026-07-23
- Primary completion:
- 2028-12-27
- Locations:
- Redlands, California, United States · San Diego, California, United States · Marietta, Georgia, United States · Skokie, Illinois, United States
- Identifier:
- NCT07716098
- RECRUITINGPHASE3Updated 2026-09-25
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Conditions:
- Depressive Disorder, Major
- Interventions:
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- Sponsor:
- Janssen Research & Development, LLC
- Enrollment:
- 258 participants
- Start:
- 2026-01-08
- Primary completion:
- 2031-04-09
- Locations:
- Birmingham, Alabama, United States · Washington D.C., District of Columbia, United States · Atlanta, Georgia, United States · Evanston, Illinois, United States
- Identifier:
- NCT07227454
- RECRUITINGPHASE4Updated 2026-09-23
Biomarker-Guided Antidepressant Selection
- Conditions:
- Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
- Interventions:
- TMS, Ketamine
- Sponsor:
- Weill Medical College of Cornell University
- Enrollment:
- 27 participants
- Start:
- 2026-08-10
- Primary completion:
- 2028-09
- Locations:
- New York, New York, United States
- Identifier:
- NCT07680140
- RECRUITINGPHASE3Updated 2026-09-17
Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation
- Conditions:
- The Critically Ill Patient is Requiring Intubation, Septic Shock, Pneumonia
- Interventions:
- Ketofol, propofol (drug)
- Sponsor:
- Helwan University
- Enrollment:
- 70 participants
- Start:
- 2026-05-13
- Primary completion:
- 2026-10
- Locations:
- Cairo, Egypt
- Identifier:
- NCT07530146
- RECRUITINGPHASE3Updated 2026-09-17
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
- Conditions:
- Status Epilepticus
- Interventions:
- Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
- Sponsor:
- University of Virginia
- Enrollment:
- 770 participants
- Start:
- 2026-03-06
- Primary completion:
- 2029-06
- Locations:
- Birmingham, Alabama, United States · Tucson, Arizona, United States · La Jolla, California, United States · Los Angeles, California, United States
- Identifier:
- NCT06907173
- RECRUITINGPHASE4Updated 2026-09-16
Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)
- Conditions:
- Suicide Prevention, Ketamine, Crisis Response Plan
- Interventions:
- Intravenous Esketamine, Crisis Response Planning (CRP), Enhanced Treatment as Usual (eTAU)
- Sponsor:
- University of Sao Paulo
- Enrollment:
- 478 participants
- Start:
- 2026-06-01
- Primary completion:
- 2028-12
- Locations:
- Indaiatuba, São Paulo, Brazil
- Identifier:
- NCT07120477
- RECRUITINGPHASE1Updated 2026-09-15
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
- Conditions:
- Healthy, Major Depressive Disorder, Treatment Resistant Depression
- Interventions:
- Ketamine, Saline
- Sponsor:
- Texas A&M University
- Enrollment:
- 100 participants
- Start:
- 2024-01-01
- Primary completion:
- 2026-12-31
- Locations:
- Houston, Texas, United States
- Identifier:
- NCT06480201
- RECRUITINGPHASE1PHASE2Updated 2026-09-15
Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD
- Conditions:
- Chronic Pain, Posttraumatic Stress Disorder (PTSD)
- Interventions:
- Ketamine Infusion, Mindfulness-based cognitive therapy
- Sponsor:
- Dr. Yuliya Knyahnytska
- Enrollment:
- 30 participants
- Start:
- 2026-03-31
- Primary completion:
- 2029-09
- Locations:
- Kingston, Ontario, Canada
- Identifier:
- NCT07009158
- RECRUITINGPHASE4Updated 2026-09-15
Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED
- Conditions:
- Pain, Acute
- Interventions:
- Ketamine, Fentanyl
- Sponsor:
- Antonios Likourezos
- Enrollment:
- 150 participants
- Start:
- 2024-05-01
- Primary completion:
- 2027-06-30
- Locations:
- Brooklyn, New York, United States
- Identifier:
- NCT06364540
- RECRUITINGNAUpdated 2026-09-11
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- Conditions:
- Obstructive Sleep Apnea, Down Syndrome
- Interventions:
- DISE-Directed Surgery, Adenotonsillectomy
- Sponsor:
- Oregon Health and Science University
- Enrollment:
- 304 participants
- Start:
- 2023-08-02
- Primary completion:
- 2027-12-31
- Locations:
- Aurora, Colorado, United States · Ann Arbor, Michigan, United States · Cincinnati, Ohio, United States · Portland, Oregon, United States
- Identifier:
- NCT05508971
- RECRUITINGPHASE1PHASE2Updated 2026-09-10
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
- Conditions:
- Depression
- Interventions:
- Ketamine-assisted psychotherapy
- Sponsor:
- Juliana Zambrano, MD, MPH
- Enrollment:
- 10 participants
- Start:
- 2025-07-23
- Primary completion:
- 2027-07-01
- Locations:
- Chelsea, Massachusetts, United States
- Identifier:
- NCT06597695
- RECRUITINGPHASE1Updated 2026-09-10
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- Conditions:
- Depression, Major Depressive Disorder, Major Depression
- Interventions:
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 70 participants
- Start:
- 2020-01-21
- Primary completion:
- 2027-02-01
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT03973268
- RECRUITINGPHASE2Updated 2026-09-09
Neurobiology of Suicide
- Conditions:
- Healthy Volunteers, Depression
- Interventions:
- Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 325 participants
- Start:
- 2015-12-01
- Primary completion:
- 2030-07-21
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT02543983
- RECRUITINGNAUpdated 2026-09-08
Quality of Recovery-15 After Opioid-free Versus Opioid-based General Anesthesia in Major Urological Surgery
- Conditions:
- Postoperative Recovery, Anesthesia, General, Analgesics, Opioid, Urologic Surgical Procedure
- Interventions:
- Remifentanil-based general anesthesia, Opioid-free general anesthesia
- Sponsor:
- Jagiellonian University
- Enrollment:
- 200 participants
- Start:
- 2026-09-02
- Primary completion:
- 2026-12-31
- Locations:
- Krakow, Lesser Poland Voivodeship, Poland
- Identifier:
- NCT07665463
- RECRUITINGUpdated 2026-09-08
Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome
- Conditions:
- Brugada Syndrome (BrS), Ventricular Arrhythmia, Anesthesia, Sedation
- Interventions:
- Not stated
- Sponsor:
- Hospital Clinic of Barcelona
- Enrollment:
- 200 participants
- Start:
- 2026-07-15
- Primary completion:
- 2028-05-31
- Locations:
- Barcelona, Barcelona, Spain
- Identifier:
- NCT07655102
- RECRUITINGUpdated 2026-09-08
Prospective Feasibility, Analgesic Effectiveness, and Safety Study of a Visual Analog Scale-Guided Multimodal Pain Algorithm After Posterior Rib Remodeling With Osteosynthesis
- Conditions:
- Acute Postoperative Pain, Chest Wall Surgery
- Interventions:
- VAS-Guided Multimodal Analgesia Algorithm, Ultrasound-Guided Thoracic Wall Regional Block
- Sponsor:
- Research Inc
- Enrollment:
- 160 participants
- Start:
- 2024-01-01
- Primary completion:
- 2025-12-12
- Locations:
- Bogotá, Colombia
- Identifier:
- NCT07805928
- RECRUITINGPHASE3Updated 2026-09-08
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Conditions:
- Depression
- Interventions:
- Racemic ketamine, Spravato (Esketamine)
- Sponsor:
- Yale University
- Enrollment:
- 400 participants
- Start:
- 2025-01-27
- Primary completion:
- 2030-12-31
- Locations:
- Milford, Connecticut, United States · New Haven, Connecticut, United States · Atlanta, Georgia, United States · Ann Arbor, Michigan, United States
- Identifier:
- NCT06713616
How to read a trial listing
Phase matters: Phase 1 studies test safety in small groups, Phase 2 looks for early signals of effect, and Phase 3 tests effectiveness against a comparator at scale. Recruitment status tells you whether enrollment is open, not whether the study has produced results. For published results, see the Research Library; for regulatory context, see the Regulatory Tracker.
Considering a trial?
Trial participation is a medical decision. Discuss any study with your own clinician, and review the study's eligibility criteria and risks on the official record before contacting a site.
About the author
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.